Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsAjantapharma

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Bull's Eye: Buy Cipla, Eveready, Emami, Concor, Godrej, EIH, Fortis Health

      Jay Thakkar of Sharekhan advises buying Bliss GVS Pharma with a target of Rs 187.

    • Support for Bank Nifty at 22450-22400; buy Infosys: Prakash Gaba

      According to Prakash Gaba of prakashgaba.com, Nifty has support at 9350-9312 and resistance at 9500 while Bank Nifty has support at 22450-22400 and resistance at 22800.

    • Like Ajanta Pharma, Jet Airways; Tata Steel may test Rs 480: Prakash Gaba

      Prakash Gaba of prakashgaba.com likes Ajanta Pharma and Jet Airways and feels that Tata Steel may test Rs 480.

    • Sell Equitas Holdings, Ajanta Pharma; buy Ambuja Cements 270 Call: Mitessh Thakkar

      Mitessh Thakkar of miteshthacker.com is of the view that one can sell Equitas Holdings and Ajanta Pharma and can buy Ambuja Cements 270 Call.

    • Buy Lupin, like Ajanta Pharma: Manoj Murlidharan

      Manoj Murlidharan of Religare Securities is of the view that Lupin is an excellent buy and likes Ajanta Pharma.

    • Hold ICICI Bank, buy Ajanta Pharma on dips: Rajesh Agarwal

      Rajesh Agarwal of AUM Capital suggests holding on to ICICI Bank and advises buying Ajanta Pharma on dips.

    • Buy ICICI Bank, prefer Ajanta Pharma: Sandeep Wagle

      Sandeep Wagle of powermywealth.com recommends buying ICICI Bank and prefers Ajanta Pharma from the pharma space.

    • Buy BEML, Motherson Sumi Systems; short United Spirits, Ajanta Pharma: Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can buy BEML and Motherson Sumi Systems and short United Spirits and Ajanta Pharma.

    • Sell Ajanta Pharma; buy Castrol India, Tata Elxsi, GMDC, HCC: Mitessh Thakkar

      Mitessh Thakkar of mitesshthakkar.com is of the view that one can sell Ajanta Pharma and can buy Castrol India, Tata Elxsi, GMDC and HCC.

    • Buy Eveready Industries, Ajanta Pharma: Mitessh Thakkar

      Mitessh Thakkar of miteshthacker.com recommends buying Eveready Industries and Ajanta Pharma.

    • Buy Transformers and Rectifiers India, Ajanta Pharma; sell Vedanta: Mitessh Thakkar

      Mitessh Thakkar of miteshthacker.com is of the view that one can buy Transformers and Rectifiers India and Ajanta Pharma while can sell Vedanta.

    • Top 5 stocks which can give up to 20% return in short term based on technicals

      While the Nifty may remain on a consolidation path, stock-specific movements could be the flavour of the week. Here is a list of top five stocks to track based on technical parameters.

    • Below Rs 1700, exit Ajanta Pharma: Rajat Bose

      According to Rajat Bose of rajatkbose.com, one may exit Ajanta Pharma if it goes below Rs 1700.

    • Hold Ajanta Pharma, says Sharmila Joshi

      According to Sharmila Joshi of sharmilajoshi.com, one may hold Ajanta Pharma.

    • Top 15 stocks which more than doubled from their 5-year average; do you own them?

      As much as 85 stocks are trading above their 5-year average price and out of that 15 stocks more than doubled from their average price recorded in the last five years.

    • Bull's Eye: Buy MCX India, Bajaj Finance, Nitin Fire, Inox Wind, Amara Raja

      Vijay Chopra of enochventures.com advises buying Reliance Capital with a target of Rs 625.

    • Bull's Eye: Buy Britannia, Sintex, Bharti Infratel, Apollo Tyre, UPL

      Vijay Chopra of enochventures.com advises buying Apollo Tyre with a target of Rs 21.

    • Buy IndusInd Bank, Ajanta Pharma, IFCI: Ashwani Gujral

      Ashwani Gujral of ashwanigujral.com recommends buying IndusInd Bank, Ajanta Pharma and IFCI.

    • Buy Reliance Industries at lower levels, prefer pharma: Ashwani Gujral

      Ashwani Gujral of ashwanigujral.com is of the view that one can buy Reliance Industries at lower levels and prefers pharma.

    • Motilal Oswal initiates buy on Ajanta Pharma with buy, expects strong US growth

    • Ajanta Pharma can head to Rs 1950; prefer Jubilant Life Sciences, Ceat, MRF: Ashwani Gujral

      Ashwani Gujral of ashwanigujral.com is of the view that Ajanta Pharma can head to Rs 1950 and prefers Jubilant Life Sciences from the pharma space and feels that one can look at Ceat and MRF from the tyre space.

    • Buy Ajanta Pharma, IndusInd Bank: Rajat Bose

      Rajat Bose of rajatkbose.com recommends buying Ajanta Pharma and IndusInd Bank.

    • Buy Ceat, Cipla, Siemens, Ajanta Pharma, Ipca Labs: Mitessh Thakkar

      Mitessh Thakkar of miteshthacker.com suggests buying Ceat, Cipla, Siemens, Ajanta Pharma and Ipca Labs.

    • Buy, sell, hold: 5 stocks analysts recommend to watch out

      CLSA has retained its buy call on Phoenix Mills, with reduced target price at Rs 460 from Rs 479. It says company's lease income growth at malls is at 6-7-quarter high despite demonetisation. Capex strategy may enable low strain capex, it feels.

    • Sell Ajanta Pharma, Engineers India: Mitessh Thakkar

      Mitessh Thakkar of miteshthacker.com suggests selling Ajanta Pharma and Engineers India.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347